Gough R, Treffy R, Krucoff M, Desai R
Cancers (Basel). 2025; 17(1.
PMID: 39796751
PMC: 11720166.
DOI: 10.3390/cancers17010124.
Wang Z, Shu J, Feng L
Future Oncol. 2024; 20(35):2757-2764.
PMID: 39268928
PMC: 11572138.
DOI: 10.1080/14796694.2024.2397327.
Indira Chandran V, Gopala S, Venkat E, Kjolby M, Nejsum P
NPJ Precis Oncol. 2024; 8(1):103.
PMID: 38760427
PMC: 11101656.
DOI: 10.1038/s41698-024-00600-2.
Neto E, de Almeida Bastos D, Yoshikawa M, Figueiredo E, Souza Filho F, Prabhu S
Neurosurg Rev. 2024; 47(1):172.
PMID: 38639882
DOI: 10.1007/s10143-024-02415-y.
Hudson E, Noutch S, Webster J, Brown S, Boele F, Al-Salihi O
BMJ Open. 2024; 14(3):e078926.
PMID: 38458809
PMC: 11145639.
DOI: 10.1136/bmjopen-2023-078926.
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study.
van den Elshout R, Herings S, Mannil M, Gijtenbeek A, Laan M, Smeenk R
Cancers (Basel). 2023; 15(20).
PMID: 37894355
PMC: 10605800.
DOI: 10.3390/cancers15204990.
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen P, van den Bent M, Youssef G, Cloughesy T, Ellingson B, Weller M
J Clin Oncol. 2023; 41(33):5187-5199.
PMID: 37774317
PMC: 10860967.
DOI: 10.1200/JCO.23.01059.
Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas.
Wu Y, Wang X, Zhang M, Wu D
Molecules. 2023; 28(15).
PMID: 37570630
PMC: 10419986.
DOI: 10.3390/molecules28155660.
Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.
Malik D, Rath T, Urcuyo Acevedo J, Canoll P, Swanson K, Boxerman J
Front Radiol. 2023; 2:809373.
PMID: 37492687
PMC: 10365126.
DOI: 10.3389/fradi.2022.809373.
The study of an anoikis-related signature to predict glioma prognosis and immune infiltration.
Zhang D, Wang Y, Zhou H, Han X, Hou L, Lv Z
J Cancer Res Clin Oncol. 2023; 149(14):12659-12676.
PMID: 37450027
DOI: 10.1007/s00432-023-05138-7.
Modifiable risk factors for glioblastoma: a systematic review and meta-analysis.
Yoshikawa M, Rabelo N, Telles J, Figueiredo E
Neurosurg Rev. 2023; 46(1):143.
PMID: 37340151
DOI: 10.1007/s10143-023-02051-y.
Assessment and prediction of glioblastoma therapy response: challenges and opportunities.
Qi D, Li J, Quarles C, Fonkem E, Wu E
Brain. 2022; 146(4):1281-1298.
PMID: 36445396
PMC: 10319779.
DOI: 10.1093/brain/awac450.
Turning on the light for brain tumor surgery: A 5-aminolevulinic acid story.
McCracken D, Schupper A, Lakomkin N, Malcolm J, Bray D, Hadjipanayis C
Neuro Oncol. 2022; 24(Suppl 6):S52-S61.
PMID: 36322101
PMC: 9629477.
DOI: 10.1093/neuonc/noac191.
Incidence and extent of disease progression on MRI between surgery and initiation of radiotherapy in glioblastoma patients.
Kraus R, Weil C, Su F, Cannon D, Burt L, Mendez J
Neurooncol Pract. 2022; 9(5):380-389.
PMID: 36134015
PMC: 9476988.
DOI: 10.1093/nop/npac044.
Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.
Hormuth 2nd D, Farhat M, Christenson C, Curl B, Quarles C, Chung C
Adv Drug Deliv Rev. 2022; 187:114367.
PMID: 35654212
PMC: 11165420.
DOI: 10.1016/j.addr.2022.114367.
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent wild-type glioblastoma.
de Groot J, Kim A, Prabhu S, Rao G, Laxton A, Fecci P
Neurooncol Adv. 2022; 4(1):vdac040.
PMID: 35611270
PMC: 9122789.
DOI: 10.1093/noajnl/vdac040.
Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma.
Pasqualetti F, Malfatti G, Cantarella M, Gonnelli A, Montrone S, Montemurro N
Radiol Med. 2022; 127(7):803-808.
PMID: 35608757
DOI: 10.1007/s11547-022-01502-8.
Pseudoprogression in low-grade glioma.
Slater J, Shih H
Transl Cancer Res. 2022; 8(Suppl 6):S580-S584.
PMID: 35117135
PMC: 8798295.
DOI: 10.21037/tcr.2019.11.16.
Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients.
Paech D, Regnery S, Platt T, Behl N, Weckesser N, Windisch P
Front Neurosci. 2021; 15:782516.
PMID: 34924945
PMC: 8671745.
DOI: 10.3389/fnins.2021.782516.
Prognostic and Predictive Biomarkers in Gliomas.
Sledzinska P, Bebyn M, Furtak J, Kowalewski J, Lewandowska M
Int J Mol Sci. 2021; 22(19).
PMID: 34638714
PMC: 8508830.
DOI: 10.3390/ijms221910373.